Marinomed Biotech said that its partner M8 Pharmaceuticals has received marketing authorization for Carragelose iota-carrageenan nasal spray in Mexico. M8 acquired the rights to market the nasal spray in Mexico and Brazil in 2021. According to the announcement, the product will be marketed in Mexico as “Barlo,” with a launch “envisaged for the next season.” Marinomed’s Carragelose products are currently marketed as an OTC product in more than 40 countries for the prevention of respiratory viruses, the company says.
M8 CEO Joel Barlan commented, “We are very pleased about the recent approval of the product by COFEPRIS and are now in the midst of launch preparations. We continue to build a market leading respiratory franchise in Mexico and throughout Latin America focused on bringing novel therapeutic solutions to patients and prescribers.”
Marinomed CEO Andreas Grassauer said, “We are very satisfied to have received the marketing authorization with our strong partner M8, while regulatory requirements for these products became more demanding worldwide. This aligns with our primary strategic goal of achieving sustainable growth for our Carragelose business by closing geographical gaps, targeting new indications and developing new products. Recently, we reported positive clinical data for the use of Carragelose in allergic indications, announced the launch of a new Carragelose eye drop product, obtained a new patent and are now expanding our respiratory product repertoire in Mexico. We are delighted by this positive development, which further motivates us to pursue our growth trajectory and leverage the success of this platform.”
Read the Marinomed press release.
